Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
33.32
+2.64 (8.60%)
At close: May 12, 2025, 4:00 PM
34.98
+1.66 (4.98%)
After-hours: May 12, 2025, 6:12 PM EDT
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $361.00K in the quarter ending March 31, 2025, a decrease of -43.59%. This brings the company's revenue in the last twelve months to $760.00K, down -61.50% year-over-year. In the year 2024, Crinetics Pharmaceuticals had annual revenue of $1.04M, down -74.11%.
Revenue (ttm)
$760.00K
Revenue Growth
-61.50%
P/S Ratio
4,107.13
Revenue / Employee
$1,739
Employees
437
Market Cap
3.12B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRNX News
- 7 hours ago - Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
- 6 weeks ago - Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire